Home
>
National Drug Code (NDC)
>
EPIVIR
EPIVIR - 49702-204-13 - (lamivudine)
Drug Information of EPIVIR
| Product NDC: | 49702-204 |
| Proprietary Name: | EPIVIR |
| Non Proprietary Name: | lamivudine |
| Active Ingredient(s): | 300 mg/1 & nbsp; lamivudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of EPIVIR
| Product NDC: | 49702-204 |
| Labeler Name: | ViiV Healthcare Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020564 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20101004 |
Package Information of EPIVIR
| Package NDC: | 49702-204-13 |
| Package Description: | 30 TABLET, FILM COATED in 1 BOTTLE (49702-204-13) |
NDC Information of EPIVIR
| NDC Code | 49702-204-13 |
| Proprietary Name | EPIVIR |
| Package Description | 30 TABLET, FILM COATED in 1 BOTTLE (49702-204-13) |
| Product NDC | 49702-204 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | lamivudine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20101004 |
| Marketing Category Name | NDA |
| Labeler Name | ViiV Healthcare Company |
| Substance Name | LAMIVUDINE |
| Strength Number | 300 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
